Managing Peripheral Facial Palsy

Annals of Emergency Medicine

Volumn 71, Issue 5, 2018, Pages 618-624

  Garro, Aris ^a   Nigrovic, Lise E ^b  

^a BROWN UNIVERSITY   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; CORTICOSTEROID THERAPY; EYE CARE; FACIAL NERVE PARALYSIS; HUMAN; MEDICAL HISTORY; PERIPHERAL FACIAL PALSY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; COMPLICATION; DIFFERENTIAL DIAGNOSIS; FACIAL NERVE INJURY; HERPES ZOSTER OTICUS; LYME DISEASE; OTITIS MEDIA; PATHOPHYSIOLOGY; PRACTICE GUIDELINE;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; DIAGNOSIS, DIFFERENTIAL; FACIAL NERVE INJURIES; FACIAL PARALYSIS; HERPES ZOSTER OTICUS; HUMANS; LYME DISEASE; OTITIS MEDIA; PRACTICE GUIDELINES AS TOPIC;

EID: 85032210553     PISSN: 01960644     EISSN: 10976760     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2017.08.039     Document Type: Review

References (49)

1. Peitersen, E., Bell's palsy: the spontaneous course of 2,500 peripheral facial nerve palsies. Acta Otolaryngol 9 (2002), 4–30.
2. Benatar, M., Edlow, J., The spectrum of cranial neuropathy in patients with Bell's palsy. Arch Intern Med 164 (2004), 2383–2385.
3. Nigrovic, L.E., Thompson, A.D., Fine, A.M., et al. Clinical predictors of Lyme disease among children with a peripheral facial palsy at an emergency department in a Lyme disease–endemic area. Pediatrics 122 (2008), e1080–e1085.
4. Halperin, J., Golightly, M., Lyme borreliosis in Bell's palsy. Long Island Neuroborreliosis Collaborative Study Group. Neurology 42 (1992), 1268–1270.
5. Tveitnes, D., Øymar, K., Natås, O., Acute facial nerve palsy in children: how often is it Lyme borreliosis?. Scand J Infect Dis 39 (2007), 425–431.
6. Engervall, K., Carlsson-Nordlander, B., Hedersteed, B., et al. Borreliosis as a cause of peripheral facial palsy: a multi-center study. ORL J Otorhinolaryngol Relat Spec 57 (1995), 202–206.
7. Peltomaa, M., Pyykkö I., Seppälä I., et al. Lyme borreliosis and facial paralysis—a prospective analysis of risk factors and outcome. Am J Otolaryngol 23 (2002), 125–133.
8. Bremell, D., Hagberg, L., Clinical characteristics and cerebrospinal fluid parameters in patients with peripheral facial palsy caused by Lyme neuroborreliosis compared with facial palsy of unknown origin (Bell's palsy). BMC Infect Dis, 11, 2011, 215.
9. Fahimi, J., Navi, B.B., Kamel, H., Potential misdiagnoses of Bell's palsy in the emergency department. Ann Emerg Med 63 (2014), 428–434.
10. Steere, A.C., McHugh, G., Damle, N., et al. Prospective study of serologic tests for Lyme disease. Clin Infect Dis 47 (2008), 188–195.
11. Centers for Disease Control and Prevention. Lyme disease maps. Available at: https://www.cdc.gov/lyme/stats/maps.html. Accessed June 7, 2017.
12. Centers for Disease Control and Prevention (CDC). Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 44 (2017), 590–591.
13. Gaillard, T., Briolant, S., Madamet, M., et al. The end of a dogma: the safety of doxycycline use in young children for malaria treatment. Malar J, 16, 2017, 148.
14. Cross, R., Ling, C., Day, N.P.J., et al. Revisiting doxycycline in pregnancy and early childhood—time to rebuild its reputation?. Expert Opin Drug Saf 15 (2016), 367–382.
15. Todd, S.R., Dahlgren, F.S., Traeger, M.S., et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain spotted fever. J Pediatr 166 (2015), 1246–1251.
16. Pachner, A.R., Steere, A., The triad of neurologic manifestations of Lyme disease: meningitis, cranial neuritis, and radiculoneuritis. Neurology 35 (1985), 47–53.
17. Hydén, D., Roberg, M., Forsberg, P., et al. Acute “idiopathic” peripheral facial palsy: clinical, serological, and cerebrospinal fluid findings and effects of corticosteroids. Am J Otolaryngol 14 (1993), 179–186.
18. Thompson, A.D., Cohn, K.A., Shah, S.S., et al. Treatment complications in children with Lyme meningitis. Pediatr Infect Dis J 31 (2012), 1032–1035.
19. Dersch, R., Freitag, M.H., Schmidt, S., et al. Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis—a systematic review. Eur J Neurol 22 (2015), 1249–1259.
20. Karlsson, M., Hammers, S., Nilsson-Ehle, I., et al. Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. Antimicrob Agents Chemother 40 (1996), 1104–1107.
21. Borg, R., Dotevall, L., Hagberg, L., et al. Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme neuroborreliosis. Scand J Infect Dis 37 (2005), 449–454.
22. Berglund, J., Stjernberg, L., Ornstein, K., et al. 5-y Follow-up study of patients with neuroborreliosis. Scand J Infect Dis 34 (2002), 421–425.
23. Hirsch, E., Sellal, F., Christmann, D., et al. [Meningoradiculitis after a tick bite. Study of 31 cases]. Rev Neurol 143 (1987), 182–188.
24. Dotevall, L., Hagberg, L., Successful oral doxycycline treatment of Lyme disease–associated facial palsy and meningitis. Clin Infect Dis 28 (1999), 569–574.
25. Karkkonen, K., Stiernstedt, S.H., Karlsson, M., Follow-up of patients treated with oral doxycycline for Lyme neuroborreliosis. Scand J Infect Dis 33 (2001), 259–262.
26. Karlsson, M., Hammers-Berggren, S., Lindquist, L., et al. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. Neurology 44 (1994), 1203–1207.
27. Kohlhepp, W., Oschmann, P., Randomized comparison of doxycycline and penicillin G. J Neurol 236 (1989), 464–469.
28. Ljøstad, U., Skogvoll, E., Eikeland, R., et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol 7 (2008), 690–695.
29. Halperin, J.J., Shapiro, E.D., Logigian, E., et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review)—report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 69 (2007), 91–102.
30. Stanek, G., Wormser, G.P., Gray, J., et al. Lyme borreliosis. Lancet 379 (2012), 461–473.
31. Sullivan, F.M., Swan, I.R.C., Donnan, P.T., et al. Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med 357 (2007), 1598–1607.
32. Engstrom, M., Berg, T., Stjernquist-Desatnik, A., et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet Neurol 7 (2008), 993–1000.
33. de Almeida, J.R., Al Khabori, M., Guyatt, G.H., et al. Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis. JAMA 302 (2009), 985–993.
34. Numthavaj, P., Thakkinstian, A., Dejthevaporn, C., et al. Corticosteroid and antiviral therapy for Bell's palsy: a network meta-analysis. BMC Neurol, 11, 2011, 1.
35. Berg, T., Bylund, N., Marsk, E., et al. The effect of prednisolone on sequelae in Bell's palsy. Arch Otolaryngol Head Neck Surg 138 (2012), 443–447.
36. Babl, F.E., Mackay, M.T., Borland, M.L., et al. Bell's Palsy in Children (BellPIC): protocol for a multicentre, placebo-controlled randomized trial. BMC Pediatr, 17, 2017, 53.
37. Axelsson, S., Berg, T., Jonsson, L., et al. Prednisolone in Bell's palsy related to treatment start and age. Otol Neurotol 32 (2011), 141–146.
38. Clark, J.R., Carlson, R.D., Sasaki, C.T., et al. Facial paralysis in Lyme disease. Laryngoscope 95 (1985), 1341–1345.
39. Kalish, R.A., Kaplan, R.F., Taylor, E., et al. Evaluation of study patients with Lyme disease, 10-20-year follow-up. J Infect Dis 183 (2001), 453–460.
40. Jowett, N., Gaudin, R.A., Banks, C.A., et al. Steroid use in Lyme disease–associated facial palsy is associated with worse long-term outcomes. Laryngoscope 127 (2016), 1451–1458.
41. Murakami, S., Mirzobuchi, M., Nakashiro, Y., et al. Bell's palsy and herpes simplex virus: identification of viral DNA in endoneural fluid and muscle. Ann Intern Med 124 (1996), 27–30.
42. Goudakos, J.K., Konstantinos, D.M., Corticosteroids vs corticosteroids plus antiviral agents in the treatment of Bell palsy. A systematic review and meta-analysis. Arch Otolaryngol Head Neck Surg 135 (2009), 558–564.
43. Hato, N., Murakami, S., Gyo, K., Steroid and antiviral treatment for Bell's palsy. Lancet 371 (2008), 1818–1820.
44. Gronseth, G.S., Paduga, R., Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 79 (2012), 2209–2213.
45. Quant, E.C., Jeste, S.S., Muni, R.H., et al. The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy: a meta-analysis. BMJ, 339, 2009, b3354.
46. Gagyor, I., Madhok, V.B., Daly, F., et al. Antiviral treatment for Bell's palsy (idiopathic facial paralysis) (review). Cochrane Database Syst Rev(11), 2015, CD001869.
47. Sullivan, F., Daly, F., Gagyor, I., Antiviral agents added to corticosteroids for early treatment of adults with acute idiopathic facial nerve paralysis (Bell palsy). JAMA 316 (2016), 874–875.
48. Hernandez, J.M., Sherbino, J., Do antiviral medications improve symptoms in the treatment of Bell's palsy?. Ann Emerg Med 69 (2017), 364–365.
49. Lee, H.Y., Byun, J.Y., Park, M.S., et al. Steroid-antiviral treatment improves the recovery rate in patients with severe Bell's palsy. Am J Med 126 (2013), 336–341.